MedPath logo

DIFFLAM SOLUTION 22.5 mg/15 ml

Pharmacy Only
Drug type: Therapeutic
ATC code: A01AD02
Dosage form: MOUTHWASH
Route of administration: ORAL
Active ingredient: BENZYDAMINE HCl; BENZYDAMINE HCl

INDICATIONS

Difflam® is indicated for the relief of painful conditions of the oral cavity including: tonsilitis, sore throat, radiation mucositis, aphthous ulcers, post orosurgical and periodontal procedures.

CONTRAINDICATIONS

Difflam® is contraindicated in patients with known hypersensitivity to benzydamine or to any of the components of the vehicle.

DOSAGE AND ADMINISTRATION

Difflam® should generally be used undiluted, but if stinging occurs it may be diluted with water.

The solution should be expelled from the mouth after use.

Uninterrupted treatment should not exceed seven days.

Dosage in Adults

When used as a gargle, the usual dose Difflam® is 15 mL (approximately one tablespoon) which should be gargled for at least 30 seconds at 1½ to 3 hourly intervals, as needed.

When used as a rinse for oral lesions, the usual dose is again 15 mL (approximately one tablespoon) which should be held in the mouth and swirled around for at least 30 seconds, with repeat use every 1½ to 3 hours throughout the day.

Dosage in Children

5–15 mL as a gargle if able to do so, or as an oral rinse.

With Impaired Renal Function

Since absorbed benzydamine and its metabolites are excreted in the urine, the possibility of systemic effects should be considered in patients with severe renal impairment.

With Impaired Liver Function

Since absorbed benzydamine is highly metabolised in the liver, possibility of systemic effects should be considered in patients with severe hepatic impairment.

Registrant
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
Approval Date
1990-04-23
Approval Number
SIN04232P
Manufacturer
Ensign Laboratories Pty Ltd
Licence Holder
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED